Brown, Nicholas F; Murray, Elizabeth R; Cutmore, Lauren C; Howard, Philip; Masterson, Luke; Zammarchi, Francesca; Hartley, John A; ... Marshall, John F; + view all Brown, Nicholas F; Murray, Elizabeth R; Cutmore, Lauren C; Howard, Philip; Masterson, Luke; Zammarchi, Francesca; Hartley, John A; Van Berkel, Patrick H; Marshall, John F; - view fewer (2024) Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancer. Pancreatology 10.1016/j.pan.2024.02.013. (In press).

Preview

Text 1-s2.0-S1424390324000577-main.pdf - Published Version Download (3MB) | Preview

Abstract

Previously we reported that a novel αvβ6-specific peptide-drug conjugate (SG3299) could eliminate established human pancreatic ductal adenocarcinoma (PDAC) xenografts. However the development of effective therapies for PDAC, which is an essential need, must show efficacy in relevant immunocompetent animals. Previously we reported that the KPC mouse transgenic PDAC model that closely recapitulates most stages of development of human PDAC, unlike in humans, failed to express αvβ6 on their tumours or metastases. In this study we have taken the KPC-derived PDAC line TB32043 and engineered a variant line (TB32043mb6S2) that expresses mouse integrin αvβ6. We report that orthotopic implantation of the αvβ6 over-expressing TB32043mb6S2 cells promotes shorter overall survival and increase in metastases. Moreover, systemic treatment of mice with established TB32043mb6S2 tumours in the pancreas with SG2399 lived significantly longer (p < 0.001; mean OS 48d) compared with PBS or control SG3511 (mean OS 25.5d and 26d, respectively). Thus SG3299 is confirmed as a promising candidate therapeutic for the therapy of PDAC.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item